Rebecca L Schacht1, Robert K Brooner2, Van L King3, Michael S Kidorf2, Jessica M Peirce2. 1. Department of Psychology, University of Maryland, Baltimore County. 2. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine. 3. Department of Psychiatry, University of Texas Health Science Center at San Antonio.
Abstract
OBJECTIVE: To determine whether contingent monetary incentives increase opioid use disorder patients' attendance to Prolonged Exposure (PE) therapy and whether attendance is associated with improvement in posttraumatic stress disorder (PTSD) and substance use disorder (SUD) outcomes. METHOD: Patients (N = 58) with PTSD were offered PE or PE with incentives (PE + I; max $480) to attend PE sessions. Participants were assessed at baseline and weeks 6, 12, and 24 postrandomization. RESULTS:Participants were mostly women (79%) and Caucasian (71%); mean age 37.43 years (SD = 11.33). PE + I participants attended a median of 9 (of 12) sessions compared to 1 session for PE participants (p < .001), which included more exposure sessions (PE + I mdn = 6; PE mdn = 0; p < .001). A Time × treatment condition interaction indicated that PE + I participants exhibited a greater decrease in PTSD severity over time than PE participants (OR = 3.1; 95% CI = 0.4-5.7; p = .024). PE + I participants remained in substance use treatment longer than PE participants (mdn days = 262 vs. 192; p = .039). There were no group differences in drug use. CONCLUSIONS: Monetary incentives increased SUD patients' attendance to an otherwise poorly attended treatment for PTSD. Better attendance in the incentivized group was associated with greater PTSD improvement, better SUD treatment retention, and no increased drug use. Incentives are well supported for improving adherence to substance use treatment goals and promising as a means to improve therapy attendance, which may improve the effectiveness of existing psychotherapies in difficult-to-treat populations. (PsycINFO Database Record (c) 2017 APA, all rights reserved).
RCT Entities:
OBJECTIVE: To determine whether contingent monetary incentives increase opioid use disorderpatients' attendance to Prolonged Exposure (PE) therapy and whether attendance is associated with improvement in posttraumatic stress disorder (PTSD) and substance use disorder (SUD) outcomes. METHOD:Patients (N = 58) with PTSD were offered PE or PE with incentives (PE + I; max $480) to attend PE sessions. Participants were assessed at baseline and weeks 6, 12, and 24 postrandomization. RESULTS:Participants were mostly women (79%) and Caucasian (71%); mean age 37.43 years (SD = 11.33). PE + I participants attended a median of 9 (of 12) sessions compared to 1 session for PEparticipants (p < .001), which included more exposure sessions (PE + I mdn = 6; PE mdn = 0; p < .001). A Time × treatment condition interaction indicated that PE + I participants exhibited a greater decrease in PTSD severity over time than PEparticipants (OR = 3.1; 95% CI = 0.4-5.7; p = .024). PE + I participants remained in substance use treatment longer than PEparticipants (mdn days = 262 vs. 192; p = .039). There were no group differences in drug use. CONCLUSIONS: Monetary incentives increased SUD patients' attendance to an otherwise poorly attended treatment for PTSD. Better attendance in the incentivized group was associated with greater PTSD improvement, better SUD treatment retention, and no increased drug use. Incentives are well supported for improving adherence to substance use treatment goals and promising as a means to improve therapy attendance, which may improve the effectiveness of existing psychotherapies in difficult-to-treat populations. (PsycINFO Database Record (c) 2017 APA, all rights reserved).
Authors: Robert K Brooner; Michael S Kidorf; Van L King; Kenneth B Stoller; Jessica M Peirce; George E Bigelow; Ken Kolodner Journal: J Subst Abuse Treat Date: 2004-10
Authors: Nancy M Petry; John M Roll; Bruce J Rounsaville; Samuel A Ball; Maxine Stitzer; Jessica M Peirce; Jack Blaine; Kimberly C Kirby; Dennis McCarty; Kathleen M Carroll Journal: J Consult Clin Psychol Date: 2008-12
Authors: Sudie E Back; Therese Killeen; Christal L Badour; Julianne C Flanagan; Nicholas P Allan; Elizabeth Santa Ana; Brian Lozano; Kristina J Korte; Edna B Foa; Kathleen T Brady Journal: Addict Behav Date: 2018-11-27 Impact factor: 3.913
Authors: Lisa M Najavits; H Westley Clark; Carlo C DiClemente; Marc N Potenza; Howard J Shaffer; James L Sorensen; Matthew T Tull; Allen Zweben; Joan E Zweben Journal: Curr Treat Options Psychiatry Date: 2020-09-24
Authors: Margaret M Gorvine; Tiffany F Haynes; S Alexandra Marshall; Cari J Clark; Nakita N Lovelady; Nickolas D Zaller Journal: J Altern Complement Med Date: 2020-12-29 Impact factor: 2.579
Authors: Tanya C Saraiya; Amber M Jarnecke; Jennifer Jones; Delisa G Brown; Kathleen T Brady; Sudie E Back Journal: Drug Alcohol Depend Date: 2021-05-21 Impact factor: 4.852
Authors: Tracy L Simpson; Simon B Goldberg; Diana K N Louden; Shannon M Blakey; Sage E Hawn; Aline Lott; Kendall C Browne; Keren Lehavot; Debra Kaysen Journal: J Anxiety Disord Date: 2021-10-26